The level of eGFR can help detect early CKD, and decreasing levels of eGFR are considered the most characteristic sign of progressive kidney disease
Among the postmenopausal-proxy group of women aged 50 and older (n = 91,577), GLP-1 RA use remained independently associated with a statistically significant OS benefit (hazard ratio, 0.87
Common side effects include: Nausea and vomiting Digestive issues like diarrhoea, constipation, or abdominal pain Headaches and fatigue Injection site reactions Serious but less common side effects: Pancreatitis Gallbladder problems Kidney problems Low blood sugar Most gastrointestinal side effects settle within the first month or two
Microbiome + SCFAs: The Foundation for Natural GLP-1 Signalling The gut microbiome ferments fiber into short-chain fatty acids (SCFAs) butyrate, propionate, acetate
Obesity and type 2 diabetes mellitus induce lipopolysaccharide tolerance in rat neutrophils